Skip to Content

'
Shannon N. Westin, MD, MPH

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

 I am a clinical investigator with a focus on developmental therapeutics and the use of biomarkers to predict response and recurrence in gynecologic cancers. My background in public health, with a focus on clinical investigation and epidemiology, has provided me with a clear understanding of the study design and validation techniques which are essential to the study of these topics. I am principal investigator of several novel treatment trials for endometrial cancer as well as a phase 1 trial of agents relevant to ovarian cancer.    As part of the Stand Up to Cancer collaboration, I serve as the MD Anderson principal investigator for a trial of MK-2206, an AKT inhibitor, in recurrent endometrial cancer. This trial incorporates a novel biomarker-driven design, utilizing stratification by PIK3CA mutation status.

Office Address

The University of Texas MD Anderson Cancer Center
1155 Herman Pressler St.
Unit Number: 1362
Houston, TX 77030
Room Number: CPB6.3279
Fax: 713-792-7586
Email: swestin@mdanderson.org

Education & Training

Degree-Granting Education

2008 The University of Texas School of Public Health, Houston, TX, MPH, Epidemiology
2002 University of Florida College of Medicine, Gainesville, FL, MD, Medicine
1998 University of Miami, Coral Gables, FL, BS, Cum Laude, Psychobiology

Postgraduate Training

7/2006-6/2010 Fellowship, Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Diane Bodurka, M.D.
7/2002-6/2006 Clinical Residency, Obstetrics and Gynecology, University of North Carolina School of Medicine, Chapel Hill, NC, Robert Strauss, M.D.

Selected Publications

Peer-Reviewed Original Research Articles

1. Westin SN, Broaddus RR, Deng L, McCampbell A, Lu KH, Lacour RA, Milam MR, Urbauer DL, Mueller P, Pickar JH, Loose DS. Molecular clustering of endometrial carcinoma based on estrogen-induced gene expression. Cancer Biol Ther 8(22):2126-35, 11/2009. e-Pub 11/2009. PMCID: PMC2872176.
2. Litton JK, Westin SN, Ready K, Sun CC, Peterson SK, Meric-Bernstam F, Gonzalez-Angulo AM, Bodurka DC, Lu KH, Hortobagyi GN, Arun BK. Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer 115(8):1598-604, 4/2009. PMCID: PMC2680417.
3. Zhang Q, Shen Q, Celestino J, Milam MR, Westin SN, Lacour RA, Meyer LA, Shipley GL, Davies PJ, Deng L, McCampbell AS, Broaddus RR, Lu KH. Enhanced estrogen-induced proliferation in obese rat endometrium. Am J Obstet Gynecol 200(2):186.e1-8, 2/2009. PMCID: PMC2880878.
4. Westin SN, Lacour RA, Urbauer DL, Luthra R, Bodurka DC, Lu KH, Broaddus RR. Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. J Clin Oncol 26(36):5965-71, 12/2008. e-Pub 11/2008. PMCID: PMC2645115.
5. Lacour RA, Daniels MS, Westin SN, Meyer LA, Burke CC, Burns KA, Kurian S, Webb NF, Pustilnik TB, Lu KH. What women with ovarian cancer think and know about genetic testing. Gynecol Oncol 111(1):132-6, 10/2008. e-Pub 8/2008. PMID: 18684498.
6. Meyer LA, Westin SN, Lu KH, Milam MR. Genetic polymorphisms and endometrial cancer risk. Expert Rev Anticancer Ther 8(7):1159-67, 7/2008. PMID: 18588460.
7. Westin SN, Bustillos D, Gano JB, Fields MM, Coker AL, Sun CC, Ramondetta LM. Social factors affecting treatment of cervical cancer: ethical issues and policy implications. Obstet Gynecol 111(3):747-51, 3/2008. PMID: 18310380.
8. Milam MR, Gu J, Yang H, Celestino J, Wu W, Horwitz IB, Lacour RA, Westin SN, Gershenson DM, Wu X, Lu KH. STK15 F31I polymorphism is associated with increased uterine cancer risk: a pilot study. Gynecol Oncol 107(1):71-4, 10/2007. e-Pub 6/2007. PMID: 17599395.
9. Westin SN, Skinner EN, Jonsson Funk M, Gehrig PM, Van Le L. Incidence of symptomatic deep venous thrombosis with epoetin alfa or darbepoetin alfa treatment of anemia in patients with ovarian or primary peritoneal cancer. Gynecol Oncol 105(2):414-7, 5/2007. e-Pub 1/2007. PMID: 17250880.
10. Westin SN. The obstetric forceps: shrouded in mystery. Obstet Gynecol Surv 61(6):357-8, 6/2006. PMID: 16719940.
11. Neville S. Ignaz Semmelweis. Primary Care Update Obstetrics/Gynecology 20:1-2, 2003.

Abstracts

1. Schlumbrecht MP, Xie S, Westin SN, Urbauer DL, Broaddus RR. Estrogen-induced gene expression predicts poor survival in high-grade serous carcinoma of the ovary. Gynecol Oncol 116:S163-4, 2010.
2. Schlumbrecht, MP, Sun CC, Westin SN, Zandstra F, Denton K, Rhodes H, Gonzales DG, Garcia EA, Levenback CL, Bodurka DC. Importance of lifestyle modification in cervical cancer survivors. J Clin Oncol 28:Abstr e15521), 2010.
3. Westin SN, Sun CC, Schlumbrecht MP, Tung CS, Lacour RA, Meyer LA, Urbauer DL, Soliman PT, Lu KH, Bodurka DC. Persistant obesity among endometrial cancer survivors: A teachable moment?. Gynecol Oncol 116:S81, 2010.
4. Huang M, Burzawa JK, Djordjevic B, McCampbell A, Boyd-Rogers A, Meyer LA, Westin SN, Broaddus RR, Lu KH. Preinvasive disease in patients with Lynch Syndrome-associated endometrial cancer 116:S97, 2010.
5. Meyer LA, Anderson ME, Lacour RA, Westin SN, Burzawa JK, Urbauer DL, Daniels MS, Burke CC, Gershenson DM, Lu KH. Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: A trend over time. Gynecol Oncol 112(2):S96, 2009.
6. Burzawa JK, Schmandt R, Bowser J, Zhang Q, Huang M, Meyer LA, Westin SN, Gershenson DM, Lu KH. Preclinical evidence for exercise and pharmacologic exercise mimetics in the treatment of endometrial cancer. Gynecol Oncol 116:S80, 2009.
7. Westin SN, Lu KH, Lacour RA, Milam MR, Urbauer, DL, Munsell MF, Loose DS, Broaddus RR. Proposed molecular diagnostics panel to guide decision-making in endometrial cancer. Gynecol Oncol 112(2):S84-85, 2009.
8. Westin SN, Lu KH, Milam MR, Lacour RA, Meyer LA, Urbauer DL, Bodurka DC, Broaddus RR. Adenocarcinoma of the lower uterine segment: A distinct clinical entity associated with Lynch Syndrome. Gynecol Oncol 108:S64, 2008.
9. Lacour RA, Westin SN, Meyer LA, Soliman PT, Keeler ER, Boyd-Rogers SG, Urbauer DL, Broaddus RR, Loose DL, Lu KH. Alterations in estrogen-associated proliferation markers in histologically-normal endometrium of obese women. J Clin Oncol 26(15S):684S, 2008.
10. Westin SN, Lu KH, Broaddus RR. Biomarker clustering segregates endometrial carcinoma into two distinct groups. Modern Pathology 21(1):228A, 2008.
11. Lacour RA, Daniels MS, Westin SN, Meyer LA, Choubey V, Blank SV, MacDonald HR, Roman L, Estes JM, Barnes M, Teoh D, Powell B, Sun CC, Urbauer DL, Ramirez PT, Bodurka DC, Gershenson DM, Lu KH. Do BRCA mutations confer a survival advantage in all cases of advanced- stage ovarian cancer?. Gynecol Oncol 108(S108), 2008.
12. Zhang Q, Celestino J, Shen Q, Milam M, Westin SN, Lacour R, Meyer L, Shipley G, Davies P, Lu K. Estrogen-induced cell proliferation and cell-cycle signaling in obese rat endometrium [abstract]. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research. [abstract]. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research:NR3037, 2008.
13. Meyer LA, Westin SN, Lacour RA, Urbauer DL, Sun CC, Daniels MS, Schmeler KM, Gershenson DM, Lu KH. Evaluating women with ovarian cancer for BRCA 1/2: missed opportunities. Gynecol Oncol 108:S67, 2008.
14. Westin SN, Lu KH, Lacour RA, Meyer LA, Xie S, Urbauer DL, Broaddus RR. GRP78 has unique expression in normal endometrium and endometrial carcinoma. Gynecol Oncol 108:S74, 2008.
15. Sun CC, Westin SN, Lacour RA, Meyer LA, Tung CS, Urbauer DL, Frumovitz MM, Gershenson DM, Lu KH, Bodurka DC. Health concerns of long term survivors of gynecologic cancers. J Clin Oncol 26(15S):727S, 2008.
16. Westin SN, Sun CC, Lacour RA, Meyer LA, Tung CS, Urbauer DL, Frumovitz MM, Lu KH, Gershenson DM, Bodurka DC. Survivors of gynecologic malignancies: Impact of treatment on health and well-being. J Clin Oncol 26(15S):299s, 2008.
17. Lacour RA, White KG, Daniels MS, Westin SN, Meyer LA, Burke CC, Burns KA, Kurian S, Webb NF, Pustilnik T, Urbauer DL, Sun CC, Bodurka DC, Gershenson DM, Lu KH. What women with ovarian cancer think and know about genetic testing. Gynecol Oncol 108:S59, 2008.
18. Sun CC, Peterson S, Lu KH, White K, Daniels M, Boyd-Rogers S, Westin SN, Bodurka DC. Women’s preferences for cancer screening strategies and prophylactic surgery. Gynecol Oncol 108:S137, 2008.
19. Westin SN, Broaddus RR. Adenocarcinoma of the lower uterine segment: a unique subset of endometrial carcinoma. Modern Pathology 21(1):227A, 2007.
20. Sun CC, Westin SN, Lu KH, Schmeler KM, White KG, Daniels MS, Arun BK, Peterson SK, Bodurka DC. Impact of BRCA 1/2 testing: Body image, sexual functioning, and quality of life. J Clin Oncol 25(18S):67S, 2007.
21. Westin SN, Sun CC, Lu KH, Schmeler KM, Soliman PT, White KG, Daniels MS, Arun BK, Peterson SK, Bodurka DC. Management strategies for women at high risk for breast and ovarian cancer: Are women satisfied?. J Clin Oncol 25(18S):67S, 2007.
22. Lacour R, Westin SN, Milam MR, Loose DS, Soliman PT, Schmeler KM, Wu W, Broaddus RR, Nabilsi NH, Urbauer DL, Nogueras-Gonzales GM, Lu KH. Molecular abnormalities in histologically normal endometrium of obese women. Gynecol Oncol 104:S29, 2007.
23. Milam MR, Gu J, Yang H, Celestino J, Wu W, Horwitz I, Lacour RA, Westin SN, Gershenson DM, Wu X, Lu KH. STK15 F31I polymorphisms and uterine cancer risk: A case-control analysis. J Clin Oncol 25(18S):276S, 2007.
24. Lacour RA, Westin SN, Daniels MS, Milam MR, Sun CC, Urbauer DU, Ramirez PT, Bodurka DC, Gershenson DM, Lu KH. Survival in advanced-stage ovarian cancer patients with non-Ashkenzi Jewish BRCA mutations. J Clin Oncol 25(18S):277S, 2007.
25. Westin SN, Cantrell L, Skinner E. Palmieri R, Gehrig P, Van Le L. The effect of Epoetin Alfa or Dabepoeitin Alfa on overall survival in patients with ovarian or primary peritoneal cancer. Gynecol Oncol 101:S86, 2006.

Last updated: 7/9/2013